Biocon

BIOCON closed at ₹362.0 on 5 November 2026, following an extreme upward gap of +5.1% that pushed the stock to the upper end of its 20-day trading range (+94.8%). Daily momentum is established (ADX 35.32), with price holding above the 20-period EMA and SMA while remaining below key longer-term averages (50-period and 200-period SMAs). This creates a mixed signal: short-term bullish structure against a broader weekly bearish trend (Supertrend bearish, ADX 26.02) and monthly weakness (ADX 11.9). Participation was high on 4 November (volume ratio 3.12) before the gap-up. The stock trades near immediate resistance at ₹362.03 and faces support at ₹355.52 (-1.79%) and ₹349.98 (-3.32%). With annualized volatility at 29.5% and a current drawdown of -17.9%, the setup requires confirmation via sustained closes above recent highs to validate a reversal from the longer-term downtrend.

Biocon Ltd reported a 57.3% decline in consolidated net profit to ₹56.7 crore for the September quarter of FY27, primarily due to a $20 million revenue recognition delay caused by logistical and geopolitical disruptions that shifted shipments to October. Despite this quarterly setback, the company forecasts a stronger second half of FY27 driven by four growth engines: rising insulin sales, ramping US biosimilars Ustekinumab and Aflibercept, and the upcoming launch of Pertuzumab in Europe and Brazil. This follows broader sector momentum, with India’s pharmaceutical index up 27% year-to-date in 2026, though analysts caution that valuations may limit further market-beating gains.

Biocon Limited disclosed unaudited financial results for the quarter and half-year ended September 30, 2026, alongside significant operational updates. For Q2 FY27, consolidated revenue from operations was ₹4,389 million with a net profit of ₹567 million (standalone) or ₹41 crore (consolidated per press release). The company secured a landmark 10-year biosimilar Pertuzumab partnership in Brazil valued at approximately USD 400 million and achieved a global patent settlement with Genentech for Pebrilzo®. Leadership changes include the resignation of Chief Technology Officer Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO effective January 1, 2027. Additionally, Biocon announced the withholding of its final dividend of ₹0.50 per share for FY 2025-26 for shareholders with incomplete KYC details.

Biocon’s FY2026-27 trajectory shows a divergence between top-line growth and bottom-line compression. Revenue rose sequentially from ₹4,336 crore in Q1 to ₹4,389 crore in Q2, yet net profit fell sharply from ₹137 crore to ₹56.7 crore. This contraction stems from rising expenses (₹4,249 crore to ₹4,362 crore) and higher finance costs (₹213 crore to ₹240 crore), which compressed Profit Before Tax from ₹128 crore to ₹54.8 crore.

Longer-term trends reinforce caution: while sales grew 10% TTM, compounded profit growth over three years remains negative at -15%. Return on Equity has declined to 1% for the last year, and ROCE dropped to 4% in Mar 2026. Cash conversion efficiency weakened significantly, with CFO/EBITDA falling to 64% in Mar 2026 from 139% the prior year. Balance-sheet leverage is shifting; while current borrowings decreased to ₹4,083 crore as of Sep 2026, non-current borrowings increased to ₹11,027 crore, and cash reserves halved from ₹4,275 crore to ₹2,204 crore over the same period. Promoter holding also diluted substantially from 60.64% to 44.68% by Sep 2026.

Biocon’s constructive case rests on a clear distinction between temporary operational headwinds and underlying business momentum. While Q2 FY27 net profit fell 57% to ₹56.7 crore due to a $20 million revenue recognition delay caused by geopolitical logistics issues, the company has explicitly forecasted a stronger second half of FY27. This anticipated recovery is driven by four specific growth engines: rising insulin sales, ramping US biosimilars (Ustekinumab and Aflibercept), and upcoming Pertuzumab launches in Europe and Brazil. Crucially, the delayed revenue is expected to be booked in Q3, providing a near-term earnings inflection point.

Technically, the stock presents a mixed but potentially stabilizing picture. The daily Supertrend remains bullish with an ADX of 35.32, suggesting underlying trend strength despite recent volatility. However, the weekly Supertrend is bearish, and the stock trades within a significant drawdown (-17.9% current, -26.6% maximum). The constructive interpretation hinges on the successful realization of the H2 FY27 catalysts and the rebooking of delayed revenues, which could support a technical rebound from the current ₹362 level toward resistance at ₹372.

Biocon faces near-term operational and valuation headwinds. Consolidated net profit plunged 57.3% to ₹56.7 crore in the September quarter of FY27, driven by a $20 million revenue recognition delay caused by geopolitical and logistical disruptions that shifted shipments to October. This quarterly setback is compounded by a deteriorating technical setup: the stock has declined 14.9% over three months and sits 17.9% below its recent peak, with a maximum historical drawdown of 26.6%. While the broader pharmaceutical sector rallied up to 112% year-to-date, Biocon’s year-to-date return remains negative at -6.6%, indicating relative underperformance. The weekly trend indicator is bearish, suggesting persistent selling pressure despite a bullish monthly signal.